Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same

Abstract

An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.

What is claimed is: 
     
         1 . A pharmaceutical dosage form, comprising delayed-release cysteamine beads, the beads comprising:
 (i) a core particle comprising cysteamine or a pharmaceutically acceptable salt thereof and a binder, and   (ii) an enteric membrane surrounding the core particle,   
       wherein the beads have a distribution of particle sizes in a range of about 0.7 mm to about 2.8 mm; 
       wherein the enteric membrane begins to dissolve within a pH range of about 4.5 to about 6.5; 
       wherein the enteric membrane is present in an amount in a range of about 20% to about 35% by weight, based on the weight of the core particles; and 
       wherein the pharmaceutical dosage form, upon administration in a capsule to fasted healthy normal subjects at 600 mg free cysteamine base, provides:
 (a) a mean Cmax upon oral dosing in a range of 2.3±0.6 mg/L or in a range of 80% to 125% thereof; and 
 (b) a mean AUC (0-inf_D) upon oral dosing in a range of 0.84±0.19 min*mg/L/mg or in a range of 80% to 125% thereof. 
 
     
     
         2 . The pharmaceutical dosage form of  claim 1 , wherein the particle sizes of the beads are in a range of about 0.7 mm to about 2.5 mm. 
     
     
         3 . The pharmaceutical dosage form of  claim 1 , wherein the distribution of bead sizes is characterized by at least 80% by weight of the beads having a particle size in a range of about 850 μm to about 1180 μm. 
     
     
         4 . The pharmaceutical dosage form of  claim 1 , wherein 5% or less of the beads by weight are retained on a #12 mesh (1.68 mm) screen and 10% or less by weight pass through a #20 mesh (0.84 mm) screen. 
     
     
         5 . The pharmaceutical dosage form of  claim 1 , wherein the distribution of bead sizes is characterized by less than 5% by weight of the beads being retained on a 1400 μm sieve. 
     
     
         6 . The pharmaceutical dosage form of  claim 1 , wherein the distribution of bead sizes is characterized by less than 30% by weight of the beads being retained on a 1180 μm sieve. 
     
     
         7 . The pharmaceutical dosage form of  claim 1 , wherein the distribution of bead sizes is characterized by less than 70% by weight of the beads being retained on a 1000 μm sieve. 
     
     
         8 . The pharmaceutical dosage form of  claim 1 , wherein the distribution of bead sizes is characterized by less than 20% by weight of the beads being retained on a 850 μm sieve. 
     
     
         9 . The pharmaceutical dosage form of  claim 1 , wherein the distribution of bead sizes is characterized by at least 15% by weight of the beads being retained on a 1180 μm sieve. 
     
     
         10 . The pharmaceutical dosage form of  claim 1 , wherein the distribution of bead sizes is characterized by at least 50% by weight of the beads being retained on a 1000 μm sieve. 
     
     
         11 . The pharmaceutical dosage form of  claim 1 , wherein the distribution of bead sizes is characterized by at least 10% by weight of the beads being retained on a 850 μm sieve. 
     
     
         12 . The pharmaceutical dosage form of  claim 1 , wherein the distribution of bead sizes is characterized by a median particle size in a range of about 850 μm to about 1180 μm. 
     
     
         13 . The pharmaceutical dosage form of  claim 1 , wherein the bead core particle further comprises a filler. 
     
     
         14 . The pharmaceutical dosage form of  claim 1 , wherein the cysteamine (as free base) is present in the bead core particle in an amount of at least 10 wt. %. 
     
     
         15 . The pharmaceutical dosage form of  claim 1 , wherein the cysteamine or pharmaceutically acceptable salt thereof is a pharmaceutically acceptable salt of cysteamine. 
     
     
         16 . The pharmaceutical dosage form of  claim 1 , wherein 5% or less of the bead core particles by weight are retained on a #12 mesh (1.68 mm) screen and 10% or less by weight pass through a #20 mesh (0.84 mm) screen. 
     
     
         17 . The pharmaceutical dosage form of  claim 1 , wherein the enteric-coated beads are characterized by acid resistance such that not more than 10% of the cysteamine in the beads is dissolved after a period of two hours in a 0.1N HCl solution. 
     
     
         18 . The pharmaceutical dosage form of  claim 1 , wherein the enteric-coated beads are characterized by dissolution such that 80% of the cysteamine or pharmaceutically acceptable salt thereof is released within 20 minutes in a solution buffered at pH 6.8. 
     
     
         19 . The pharmaceutical dosage form of  claim 1 , further comprising a capsule shell enclosing the plurality of beads. 
     
     
         20 . The pharmaceutical dosage form of  claim 1 , wherein the beads provide a mean Cmax and mean AUC (0-inf_D) upon oral dosing, fasted, when administered inside a capsule shell that are bioequivalent to the mean Cmax and mean AUC (0-inf_D) upon oral dosing, fasted, when administered without a capsule shell.